Phio Pharmaceuticals Corp (PHIO) Stock Price, Quote & News

Company Profile

Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma a...

Industry: Biotechnology

Sector: Healthcare

Phone: 508 767 3861

Website: phiopharma.com

Address:

11 Apex Drive, Suite 300A PMB 2006, Marlborough, United States

JEB6 Nov. 20 at 11:01 PM

$PHIO

0 · Reply

PitaPierogi Nov. 20 at 10:27 PM

$PHIO Warrant shares DO NOT EXIST in the market unless the holders exercise them by paying $2.05/share. Since PHIO is trading at $1.19, exercising warrants right now would be: Paying $2.05 For stock worth $1.19 → They would lose money. So no exercises happen and no new shares hit the float at this price.

0 · Reply

ckruel Nov. 20 at 9:44 PM

$PHIO files to sell 11.76 million shares to holders…..

0 · Reply

Stripette Nov. 20 at 9:37 PM

$PHIO why is it going up?

0 · Reply

PitaPierogi Nov. 20 at 8:32 PM

$PHIO algos hard at work. Soon they'll turn to buy and we'll see 4's 5's

0 · Reply

Treechain Nov. 20 at 6:10 PM

$PHIO news of partnership is imminent . They already have production pipeline in place. but they will have some interested parties wanting to take this to other forms of cancer. HOLD for the gold

1 · Reply

ckruel Nov. 20 at 2:15 PM

$PHIO H.C. Wainwright analyst Matthew Keller reiterated a Buy rating on Phio Pharmaceuticals today and set a price target of $14.00

0 · Reply

PitaPierogi Nov. 19 at 10:25 PM

$PHIO lmao

0 · Reply

Roaring_Capybara Nov. 19 at 10:25 PM

$PHIO What the Phuk happened. Did they flip the massive 5k share purchase ..... 🤣

0 · Reply

newbulloh2 Nov. 19 at 9:56 PM

$PHIO yess!!! We have buyers!!!!!!!!!!!!!

0 · Reply

Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress

Nov 13, 2025, 4:15 PM EST - 7 days ago

Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 7, 2025, 10:30 AM EST - 13 days ago

Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762

Nov 7, 2025, 7:45 AM EST - 13 days ago

Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program

Nov 3, 2025, 1:40 PM EST - 17 days ago

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds

Nov 3, 2025, 7:45 AM EST - 17 days ago

Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial

Oct 31, 2025, 10:15 AM EDT - 20 days ago

Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

Oct 21, 2025, 7:45 AM EDT - 4 weeks ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Sep 18, 2025, 7:45 AM EDT - 2 months ago

Phio Pharmaceuticals to Present at the Life Sciences Future Conference

Sep 3, 2025, 7:45 AM EDT - 2 months ago

Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 4:15 PM EDT - 3 months ago

Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 25, 2025, 3:04 PM EDT - 4 months ago

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

Jul 25, 2025, 12:36 PM EDT - 4 months ago

Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

Jul 25, 2025, 7:45 AM EDT - 4 months ago

Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance

Jun 25, 2025, 7:45 AM EDT - 5 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort

Jun 24, 2025, 7:45 AM EDT - 5 months ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Jun 6, 2025, 7:45 AM EDT - 5 months ago

Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio

May 19, 2025, 7:45 AM EDT - 6 months ago

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference

May 15, 2025, 4:15 PM EDT - 6 months ago

Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025, 7:45 AM EDT - 7 months ago

Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial

Apr 9, 2025, 7:45 AM EDT - 8 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort

Apr 3, 2025, 7:45 AM EDT - 8 months ago

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894

Mar 31, 2025, 4:00 PM EDT - 8 months ago

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

Mar 10, 2025, 7:45 AM EDT - 9 months ago

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting

Mar 5, 2025, 7:45 AM EST - 9 months ago

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

Feb 20, 2025, 7:45 AM EST - 9 months ago

Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

Jan 22, 2025, 7:00 AM EST - 10 months ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Jan 21, 2025, 4:15 PM EST - 10 months ago

Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 16, 2025, 1:00 PM EST - 11 months ago

Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 15, 2025, 7:00 AM EST - 11 months ago

Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 14, 2025, 7:00 AM EST - 11 months ago

Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 13, 2025, 12:45 PM EST - 11 months ago

Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why

Jan 13, 2025, 7:45 AM EST - 11 months ago

Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762

Jan 2, 2025, 7:45 AM EST - 11 months ago

Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology

Dec 23, 2024, 1:15 PM EST - 11 months ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 19, 2024, 2:28 PM EST - 1 year ago

Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 19, 2024, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762

Dec 12, 2024, 9:21 AM EST - 1 year ago

Phio Pharmaceuticals Announces Publication in Frontiers in Immunology

Dec 10, 2024, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award

Nov 19, 2024, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study

Nov 14, 2024, 5:47 PM EST - 1 year ago

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 10:00 AM EST - 1 year ago

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 18, 2024, 1:30 PM EDT - 1 year ago

Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Oct 18, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells

Sep 25, 2024, 8:00 AM EDT - 1 year ago

INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society

Sep 16, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024, 5:00 PM EDT - 1 year ago

Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

JEB6 Nov. 20 at 11:01 PM

$PHIO

0 · Reply

PitaPierogi Nov. 20 at 10:27 PM

0 · Reply

ckruel Nov. 20 at 9:44 PM

$PHIO files to sell 11.76 million shares to holders…..

0 · Reply

Stripette Nov. 20 at 9:37 PM

$PHIO why is it going up?

0 · Reply

PitaPierogi Nov. 20 at 8:32 PM

$PHIO algos hard at work. Soon they'll turn to buy and we'll see 4's 5's

0 · Reply

Treechain Nov. 20 at 6:10 PM

$PHIO news of partnership is imminent . They already have production pipeline in place. but they will have some interested parties wanting to take this to other forms of cancer. HOLD for the gold

1 · Reply

ckruel Nov. 20 at 2:15 PM

$PHIO H.C. Wainwright analyst Matthew Keller reiterated a Buy rating on Phio Pharmaceuticals today and set a price target of $14.00

0 · Reply

PitaPierogi Nov. 19 at 10:25 PM

$PHIO lmao

0 · Reply

Roaring_Capybara Nov. 19 at 10:25 PM

$PHIO What the Phuk happened. Did they flip the massive 5k share purchase ..... 🤣

0 · Reply

newbulloh2 Nov. 19 at 9:56 PM

$PHIO yess!!! We have buyers!!!!!!!!!!!!!

0 · Reply

DERDER Nov. 19 at 8:55 PM

$PHIO Lots of huge purchases over the last week.

1 · Reply

CEOBuysDisclosures Nov. 19 at 7:50 PM

$PHIO CEO purchased 5,000 shares at $1.27 for a total of $6,350. Bitterman Robert J now owns 276,421 shares. https://ceo-buys.com

0 · Reply

Treechain Nov. 19 at 6:54 PM

$PHIO well that was a fake head nod as it continues down the staircase lol

0 · Reply

Treechain Nov. 19 at 6:08 PM

$PHIO somebody just bought 80,000 shares in 60 seconds

0 · Reply

Treechain Nov. 19 at 6:06 PM

$PHIO somebody just bought a chunk hard

0 · Reply

Treechain Nov. 19 at 5:15 PM

$PHIO volume down to dust particles floating around. The wait for next PR may be excrusiating.

0 · Reply

DERDER Nov. 19 at 3:49 PM

$PHIO Just like PHIO in the near term, will be smokin…

0 · Reply

PitaPierogi Nov. 19 at 3:34 PM

$PHIO

0 · Reply

DosGatos Nov. 19 at 3:28 PM

$PHIO Phio’s other “pipelines”:

0 · Reply

PitaPierogi Nov. 19 at 3:08 PM

$PHIO PHIO’s Other Pipelines: PH-894: Preclinical results show it helps the immune system recognize tumors better. Activates T cells effectively, making it a strong immunotherapy candidate. PH-804: Targets TIGIT to boost natural killer cell activity in preclinical models. Shows promise in enhancing immune response against tumors. Timeline and Funding: They’re aiming to move these into clinical trials possibly next year. Recent warrant funding should support these next steps, giving them a solid cash runway.

0 · Reply

Bigmoney47 Nov. 19 at 2:37 PM

$PHIO today 1$ or 1.50 still hold

0 · Reply

Stock__Hunter Nov. 18 at 10:35 PM

$PHIO Don't like to toot my own horn. follow the yellow brick road💋💯

0 · Reply

Market Cap	7.27M
Revenue (ttm)	0.00
Net Income (ttm)	-7.15M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	462,500
Avg Vol	3,550,662
Day's Range	N/A - N/A
Shares Out	5.73M
Stochastic %K	11%
Beta	0.96
Analysts	Sell
Price Target	$14.00